A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

Prior treatment

• Received renal dialysis within 12 months preceding screening, or anticipated requirement for dialysis/renal transplantation within 6 months post-enrollment;
• Catastrophic antiphospholipid syndrome (APS) within 12 months pre-screening, or APS-related thrombotic events (except non-catastrophic/mild APS cases with stable anticoagulation ≥12 weeks prior to screening);

Other illness

• Non-LN renal diseases potentially confounding disease assessment (e.g., diabetic nephropathy per investigator judgment);
• Inflammatory/autoimmune diseases beyond SLE/LN that may interfere with efficacy/safety interpretation.

Other

• Renal biopsy demonstrating \> 50% globally sclerosed glomeruli;
• Active severe/unstable neuropsychiatric SLE (NPSLE);

• Age 18-70 years (inclusive) at informed consent signing, regardless of sex;
• Body weight ≥ 40.0 kg and body mass index (BMI) ≥ 16 kg/m² to ≤ 28 kg/m² at screening;
• Diagnosed with systemic lupus erythematosus (SLE) per 1997 ACR criteria or 2019 EULAR/ACR classification criteria;
• Positive antinuclear antibody (titer ≥ 1:80) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening;
• Histologically confirmed active lupus nephritis (LN) class III or IV ± class V by renal biopsy, per 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) standards within 1 year preceding or during screening.